Predicine Closes Series A Financing Totaling $13.5M
Predicine, a Hayward, Calif.-based precision medicine company, today announced it has completed its $13.5M Series A financing from Sangel Capital, Rongsheng Investment, and Highlight Capital.
Predicine provides an integrated oncology biomarker solution that includes an innovative RNA+DNA liquid biopsy test and a one-stop biomarker and data analysis platform to support targeted cancer therapeutics and global clinical trials.
The funding will help Predicine focus its efforts to expand the commercialization of its next-generation liquid biopsy technology and its application in clinical trials, treatment selection, and cancer screening. In addition, Predicine will continue to develop new pipeline to provide an integrated oncology biomarker solution to accelerate global clinical trials.
Pan Du, Predicine CTO and co-founder, said, “Predicine has developed an innovative liquid biopsy test using its proprietary GeneRADAR technology to detect RNA- and DNA-based genetic alterations from a single tube of blood. This enables the test to capture a broader range of clinically important genetic variants, such as gene fusion and splicing events, in a more efficient way than other DNA-only blood tests currently available.”
“Our team is very excited to partner with visionary investors to bring the latest technology to cancer patients worldwide. Our mission is to empower the global healthcare ecosystem through innovation. This investment will allow us to expand our current capabilities and bring this innovative technology to advance precision oncology in patient care and clinical trials.” added Shidong Jia, CEO and Founder.
Dr. Nanxing He, Partner of Sangel Capital said, “Sangel is focused on health care investment. Our team has been looking for high quality team to invest in. Predicine stood out because of its superior technology and experienced team. Further, Predicine’s RNA+DNA liquid biopsy technology has been confirmed by various pharmaceutical organizations which increases our confidence in this investment.”
Predicine is a global precision medicine company committed to promoting personalized cancer care. With its patented GeneRADAR technology, Predicine offers blood-based molecular diagnostics test that enables the tracking and sequencing of a patient’s cancer in real-time without the need of a tissue biopsy, identifies predictive biomarkers, and matches these identified genetic alterations with targeted therapeutic options and clinical trials. The company was incorporated in 2015 and operates in Hayward, California and Shanghai, China.